VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 7, 2012, Pages

  Oltean, Sebastian ^a   Neal, Christopher R ^a   Mavrou, Athina ^a   Patel, Panisha ^a   Ahad, Thomas ^a   Alsop, Chloe ^a   Lee, Thomas ^a   Sison, Karen ^b   Qiu, Yan ^a   Harper, Steven J ^a   Bates, David O ^a   Salmon, Andrew H J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Glomerulus; Permeability; Podocyte; Proteinuria; VEGF

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 164; VASCULOTROPIN 165; VASCULOTROPIN 165 B; VASCULOTROPIN A; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; KIDNEY DISEASE; KIDNEY FUNCTION; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; SUBPODOCYTE SPACE; TRANSGENIC MOUSE; ULTRAFILTRATION; WATER PERMEABILITY; ANIMAL; BODY WATER; GENETICS; GLOMERULUS; METABOLISM; PERMEABILITY;

ANIMALS; BODY WATER; KIDNEY GLOMERULUS; MICE; MICE, TRANSGENIC; PERMEABILITY; PODOCYTES; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867116499     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00410.2011     Document Type: Article

References (41)

1. Ansell D, Feehally J, Fogarty D, Ford D, Hodsman A, Tomson C, Udayaraj U, Warwick G, Williams A. UK Renal Registry 11th Annual Report. Bristol, UK: UK Renal Registry, 2008.
2. Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 43: 636-650, 2004.
3. Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248: 1224-1227, 1990.
4. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62: 4123-4131, 2002.
5. Bevan HS, van den Akker NM, Qiu Y, Polman JA, Foster RR, Yem J, Nishikawa A, Satchell SC, Harper SJ, Gittenberger-Degroot AC, Bates DO. The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol 110: p57-67, 2008.
6. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000, 2001.
7. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 281: F579-F596, 2001.
8. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 106: 32-37, 2007.
9. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008.
10. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. Glomerular-specific alteradiseases. J Clin Invest 111: 707-716, 2003.
11. Fissell WH, Hofmann CL, Ferrell N, Schnell L, Dubnisheva A, Zydney AL, Yurchenco PD, Roy S. Solute partitioning and filtration by extracellular matrices. Am J Physiol Renal Physiol 297: F1092-F1100, 2009.
12. Glass CA, Harper SJ, Bates DO. The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo. J Physiol 572: 243-257, 2006.
13. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88: 451-487, 2008.
14. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8: 880-887, 2008.
15. Jeansson M, Bjorck K, Tenstad O, Haraldsson B. Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol 20: 114-122, 2009.
16. Katavetin P. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 359: 205-206; author reply 206-207, 2008.
17. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan CE, Peltonen L, Holmberg C, Olsen A, Tryggvason K. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1: 575-582, 1998.
18. Ma J, Matsusaka T, Yang HC, Zhong J, Takagi N, Fogo AB, Kon V, Ichikawa I. Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside. Pediatr Res 70: 83-89, 2011.
19. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 292: F1665-F1672, 2007.
20. Neal CR, Crook H, Bell E, Harper SJ, Bates DO. Three-dimensional reconstruction of glomeruli by electron microscopy reveals a distinct restrictive urinary subpodocyte space. J Am Soc Nephrol 16: 1223-1235, 2005.
21. Neal CR, Muston PR, Njegovan D, Verrill R, Harper SJ, Deen WM, Bates DO. Glomerular filtration into the subpodocyte space is highly restricted under physiological perfusion conditions. Am J Physiol Renal Physiol 293: F1787-F1798, 2007.
22. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 285: 5532-5540, 2010.
23. Pagtalunan ME, Rasch R, Rennke HG, Meyer TW. Morphometric analysis of effects of angiotensin II on glomerular structure in rats. Am J Physiol Renal Fluid Electrolyte Physiol 268: F82-F88, 1995.
24. Qiu Y, Ferguson J, Oltean S, Neal CR, Kaura A, Bevan H, Wood E, Sage LM, Lanati S, Nowak DG, Salmon AH, Bates D, Harper SJ. Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol 21: 1498-1509, 2010.
25. Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 17: 208-212, 1963.
26. Salmon AH, Neal CR, Bates DO, Harper SJ. Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli. J Physiol 570: 141-156, 2006.
27. Salmon AH, Toma I, Sipos A, Muston PR, Harper SJ, Bates DO, Neal CR, Peti-Peterdi J. Evidence for restriction of fluid and solute movement across the glomerular capillary wall by the subpodocyte space. Am J Physiol Renal Physiol 293: F1777-F1786, 2007.
28. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 51: 714-725, 2008.
29. Savin VJ, Terreros DA. Filtration in single isolated mammalian glomeruli. Kidney Int 20: 188-197, 1981.
30. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017, 2004.
31. Schrijvers BF, Rasch R, Tilton RG, Flyvbjerg A. High protein-induced glomerular hypertrophy is vascular endothelial growth factor-dependent. Kidney Int 61: 1600-1604, 2002.
32. Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS, Bulla M, Royer-Pokora B. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol 18: 719-729, 2007.
33. Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG, Quaggin SE. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21: 1691-1701, 2010.
34. Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, Jimenez J, Velazquez H, Kashgarian M, Moeckel GW, Tufro A. Podocyte vascular endothelial growth factor (Vegf) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 54: 1227-1241, 2011.
35. Veron D, Reidy K, Marlier A, Bertuccio C, Villegas G, Jimenez J, Kashgarian M, Tufro A. Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndrome. Am J Pathol 177: 2225-2233, 2010.
36. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB, Tufro A. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 77: 989-999, 2010.
37. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308: 1801-1804, 2005.
38. Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21: 1381-1389, 2010.
39. Yang XH, Man XY, Cai SQ, Yao YG, Bu ZY, Zheng M. Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. Biochem Biophys Res Commun 349: 31-38, 2006.
40. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193, 2007.
41. Ziyadeh FN. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract 82, Suppl 1: S38-41, 2008.